Product Description
Mechanisms of Action: 5-HT1A Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Daiichi Sankyo
Company Location: TOKYO M0 103-8426
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Ischemic Stroke|Stroke|Parkinson's Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ASBI-501 | P2 |
Completed |
Parkinson's Disease |
2008-07-17 |
|
2004-002437-39 | P2 |
Terminated |
Stroke |
2006-10-24 |
|
SPI-103 | P2 |
Terminated |
Ischemic Stroke |
2006-10-01 |